80173
document
Poylmerized whole ragweed : an improved method of immunotherapy . A single-blind study compared the effectiveness of glutaraldehyde-treated polymerized ragweed with nonpolymerized monomeric ragweed . These studies are an extension of those previously reported for polymerized AgE using a readily available ragweed preparation containing all ragweed antigens . Nineteen ragweed-sensitive patients were randomized into 2 groups ; 10 received the polymerized form and 9 received the monomeric form . Four parameters were followed : serum-specific IgE against antigen E , total blocking antibody against antigen E , local and systemic reactions to injection therapy , and symptom score indices . Pretreatment levels of antigen E -- specific IgE and blocking antibody activity were similar in both groups . After a total of 15,000 protein nitrogen units ( PNU ) had been given , blocking antibody activity in the monomer group rose from a mean of 170 ng AgE bound per ml to a mean of 2,813 . The rise in blocking antibody activity in the polymer group was from a mean of 181 ng AgE bound per ml to 1,574 . At 15,000 PNU , blocking antibody activity levels were not statistically different in the 2 groups . After 1 year of treatment , no consistent decrease in postseasonal specific IgE rise could be shown in either group . Forty times less erythema and 15 times less induration were found with polymerized ragweed . There were 7 systemic reactions with the monomer and none with the polymer . Both groups experienced symptomatic improvement with treatment .
80174
Intervention_Pharmacological
Poylmerized whole ragweed
80175
Intervention_Pharmacological
glutaraldehyde-treated polymerized ragweed
80176
Intervention_Pharmacological
nonpolymerized monomeric ragweed .
80177
Intervention_Pharmacological
ragweed
80178
Intervention_Pharmacological
polymerized form
80179
Intervention_Pharmacological
monomeric form
80180
Intervention_Pharmacological
polymerized ragweed
80181
Outcome_Physical
blocking antibody activity
80182
Outcome_Physical
rise in blocking antibody activity
80183
Outcome_Physical
blocking antibody activity levels
80184
Outcome_Physical
postseasonal specific IgE rise
80185
Outcome_Physical
erythema
80186
Outcome_Physical
induration
80187
Outcome_Adverse-effects
systemic reactions
80188
Outcome_Other
symptomatic improvement
80189
Participant_Sample-size
Nineteen
80190
Participant_Condition
ragweed-sensitive
80191
Participant_Condition
were randomized into 2 groups ;
80192
Participant_Sample-size
10
80193
Participant_Condition
and
80194
Participant_Sample-size
9
80195
Participant_Condition
.